Consistently, it is believed that inactivated, aggregation-prone GAPDH can enhance such pathologies as Alzheimer’s disease [75], Huntington’s disease [76,77], Parkinson’s disease [78], diabetes [79], secondary damage after traumatic brain injury [28] and many others. This evidence concerns the gene GAPDH and juvenile Huntington disease.